TY - JOUR
T1 - Novel tracers for molecular imaging of interstitial lung disease
T2 - A state of the art review
AU - Broens, Bo
AU - Duitman, Jan-Willem
AU - Zwezerijnen, Gerben J. C.
AU - Nossent, Esther J.
AU - van der Laken, Conny J.
AU - Voskuyl, Alexandre E.
N1 - Funding Information: None. Publisher Copyright: © 2022 The Authors
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Interstitial lung disease is an overarching term for a wide range of disorders characterized by inflammation and/or fibrosis in the lungs. Most prevalent forms, among others, include idiopathic pulmonary fibrosis (IPF) and connective tissue disease associated interstitial lung disease (CTD-ILD). Currently, only disease modifying treatment options are available for IPF and progressive fibrotic CTD-ILD, leading to reduction or stabilization in the rate of lung function decline at best. Management of these patients would greatly advance if we identify new strategies to improve (1) early detection of ILD, (2) predicting ILD progression, (3) predicting response to therapy and (4) understanding pathophysiology. Over the last years, positron emission tomography (PET) and single photon emission computed tomography (SPECT) have emerged as promising molecular imaging techniques to improve ILD management. Both are non-invasive diagnostic tools to assess molecular characteristics of an individual patient with the potential to apply personalized treatment. In this review, we encompass the currently available pre-clinical and clinical studies on molecular imaging with PET and SPECT in IPF and CTD-ILD. We provide recommendations for potential future clinical applications of these tracers and directions for future research.
AB - Interstitial lung disease is an overarching term for a wide range of disorders characterized by inflammation and/or fibrosis in the lungs. Most prevalent forms, among others, include idiopathic pulmonary fibrosis (IPF) and connective tissue disease associated interstitial lung disease (CTD-ILD). Currently, only disease modifying treatment options are available for IPF and progressive fibrotic CTD-ILD, leading to reduction or stabilization in the rate of lung function decline at best. Management of these patients would greatly advance if we identify new strategies to improve (1) early detection of ILD, (2) predicting ILD progression, (3) predicting response to therapy and (4) understanding pathophysiology. Over the last years, positron emission tomography (PET) and single photon emission computed tomography (SPECT) have emerged as promising molecular imaging techniques to improve ILD management. Both are non-invasive diagnostic tools to assess molecular characteristics of an individual patient with the potential to apply personalized treatment. In this review, we encompass the currently available pre-clinical and clinical studies on molecular imaging with PET and SPECT in IPF and CTD-ILD. We provide recommendations for potential future clinical applications of these tracers and directions for future research.
KW - Connective tissue disease
KW - Interstitial lung disease
KW - Molecular imaging
KW - Positron emission tomography
KW - Pulmonary fibrosis
KW - Single photon emission computed tomography
UR - http://www.scopus.com/inward/record.url?scp=85139679274&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85139679274&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36150433
U2 - https://doi.org/10.1016/j.autrev.2022.103202
DO - https://doi.org/10.1016/j.autrev.2022.103202
M3 - Review article
C2 - 36150433
SN - 1568-9972
VL - 21
SP - 103202
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 12
M1 - 103202
ER -